|
|
|
|
|
|
| Abstract Search | Browse Program and Abstracts | Schedule-at-a-Glance | Conference Mission & Sponsors | Program Committee | Contact Us |
| # | Title |
|---|---|
| 241 | Long-Term Follow-Up: No Effect of Therapeutic Vaccination with HIV-1 P17/P24:Ty Virus-Like Particles on HIV-1 Disease Progression
C. Lindenburg1, I. Stolte1, M. Langendam1, F. Miedema2,3, and R. Coutinho*1,3, on behalf of the participating centers 1Municipal Hlth. Service of Amsterdam, The Netherlands; 2CLB/Sanquin, Amsterdam, The Netherlands; and 3Academic Med. Ctr., Amsterdam, The Netherlands |
| 242 | Viral Rebound after Immunotherapy by HIV Lipopeptides and HAART Interruption in Patients Chronically Infected by HIV
D. Salmon*1, G. Pialoux2, H. Gahery1, N. Daniel1, A. Krivine1, T. Tuyen2, D. Sicard1, W. Rozenbaum2, and J. G. Guillet1 1Cochin Hosp. and 2Rothschild Hosp., Paris, France |
| 243 | Therapeutic Immunization with REMUNE Alters Kinetics of Viral Rebound after Analytical Therapy Interruption
R. P. Bucy*1, R. Moss2, M. Gersten3, and the 806A Study Team 1Univ. of Alabama at Birmingham, USA; 2Immune Response Corp., Carlsbad, CA, USA; and 3Agouron Pharmaceuticals, La Jolla, CA, USA |
| 244 | Tetanus and Diphtheria Antibody Levels: Response to a Booster Dose in HIV-1-Infected Children under HAART
D. M. Takano*, R. C. M. Succi, A. M. Rufino, and M. I. de Moraes-Pinto Federal Univ. of São Paulo, Brazil |
| 245 | Immune Responses and Reconstitution in HIV-1-Infected Individuals: Impact of Antiretroviral Therapy, Cytokines, and Therapeutic Vaccines
F. Gotch*1, N. Imami1, G. Hardy1, C. Burton1, A. Pirez1, R. Moss2, and B. Gazzard3 1Imperial Coll. Sch. of Med., London, UK; 2Immune Response Corp., Carlsbad, CA, USA; and 3Chelsea and Westminster Hosp., London, UK |
| 246 | Detection of HIV-1 RNA in Peripheral Blood Mononuclear Cells of Patients
Receiving Prolonged Highly Active Antiviral or Vaccine Therapy
J. Zhang and C. S. Crumpacker* Beth Israel Deaconess Med. Ctr., Harvard Med. Sch, Boston, MA, USA |
| 247 | Structural Similarities between Influenza Virus and HIV Matrix Proteins Results in Cross-Recognition by T Cells from Both HIV-Infected and Uninfected Individuals
P. M. Acierno, D. A. Newton, E. A. Brown, L. Maes, J. E. Baatz, and S. Gattoni-Celli* Med. Univ. of South Carolina, Charleston, USA |
| 248 | Anti-HIV-1 CD4+and CD8+T-Cell Responses in Chronically HIV-1-Infected Patients Treated with HAART: Relevance for Specific Immunotherapy
N. Daniel*1,4, G. Pialoux2, H. Gahery1 M. Andrieu1, T. NGuyen2, P. M. Girard2 W. Rozenbaum2, H. Gras-Masse3, D. Sicard4, D. Salmon4, and J. G. Guillet1 1ICGM, Paris, France; 2 Hôsp. Rothschild, Paris, France; 3 Inst. Pasteur, Lille, France; and 4 Hôsp. Cochin, Paris, France |
| 249 | DNA Vaccine Induction of T-Cell Responses prior to Infection Augments the Efficacy of Immunotherapy during HAART Post-Infection
D. Fuller1, M. S. Wu1, P. Rajakumar2, T. Allen3, S. Capuano2, J. T. Fuller1, T. Shipley1, R. Rudersdorf3, A. Sette4, J. R. Haynes1, D. I. Watkins3, and M. Murphey-Corb*2 1Powderject Vaccines, Madison, WI, USA; 2Univ. of Pittsburgh, PA, USA; 3Univ. of Wisconsin, Madison, USA; and 4Epimmune, San Diego, CA, USA |
| 250 | Concomitant Administration of Two Facilitated DNA Plasmid Vaccines Containing HIV-1 Env/Rev and Gag/Pol Genes in HIV-Infected Patients on HAART: Safety, Immune Testing, and Plasma Virus Levels
R. MacGregor*1, J. Boyer1, R. Ginsberg2, T. Higgins2, R. Ciccarelli2, J. Eldridge2, and D. Weiner1 1Univ. of Pennsylvania, Philadelphia, USA and 2Wyeth-Lederle Vaccines, Pearl River, NY, USA |